General
Preferred name
estradiol valerate
Synonyms
¦Â-Estradiol 17-valerate ()
??Estradiol 17-valerate ()
E2V ()
β-Estradiol 17-valerate ()
Progynova ()
.beta.-estradiol 17-valerate ()
Femtab ()
Estradiol valerate component of ditate-ds ()
NSC-17590 ()
Progynon-Depot-10 ()
Climaval ()
Estradiol 17-valerate ()
Estradiol valerate component of natazia ()
Delestrogen ()
Progynon Depot ()
Deladumone ()
Valerato de estradiol ()
Valerate d'estradiol ()
?-Estradiol 17-valerate ()
P&D ID
PD003187
CAS
979-32-8
69557-95-5
Tags
available
drug
prodrug
Approved by
FDA
First approval
1954
1982
Drug indication
Infertility
Hormone replacement therapy
Drug Status
approved
investigational
vet_approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Estradiol valerate is a synthetic ester of the endogenous estrogen, . This ester is absorbed more slowly and has a longer duration of action than the native hormone. Estradiol valerate is cleaved in vivo by plasma and liver esterases to form 17β-estradiol and valeric acid.
(GtoPdb)
MOA
Estradiol enters target cells freely (e.g., female organs, breasts, hypothalamus, pituitary) and interacts with a target cell receptor. When the estrogen receptor has bound its ligand it can enter the nucleus of the target cell, and regulate gene transcription which leads to formation of messenger RNA. The mRNA interacts with ribosomes to produce specific proteins that express the effect of estradiol upon the target cell. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary.; ; Increases in the down-stream effects of ER binding reverses some of the symptoms of menopause, which are primarily caused by a loss of estrogenic activity.
INDICATION
Estradiol valerate is commercially available as an intramuscular injection as the product Delestrogen and is indicated for the treatment of moderate to severe vasomotor symptoms and vulvovaginal atrophy due to menopause, for the treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and for the treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). ; ; Estradiol valerate is also available in combination with [DB09123] as the commercially available product Natazia used for the prevention of pregnancy and for the treatment of heavy menstrual bleeding.
ABSORPTION
IM Injection: When conjugated with aryl and alkyl groups for parenteral administration, the rate of absorption of oily preparations is slowed with a prolonged duration of action, such that a single intramuscular injection of estradiol valerate or estradiol cypionate is absorbed over several weeks [FDA Label].; ; Natazia: After oral administration of estradiol valerate, cleavage to 17β-estradiol and valeric acid takes place during absorption by the intestinal mucosa or in the course of the first liver passage. This gives rise to estradiol and its metabolites, estrone and other metabolites. Maximum serum estradiol concentrations of 73.3 pg/mL are reached at a median of approximately 6 hours (range: 1.5â12 hours) and the area under the estradiol concentration curve [AUC(0â24h)] was 1301 pg·h/mL after single ingestion of a tablet containing 3 mg estradiol valerate under fasted condition on Day 1 of the 28-day sequential regimen.
DESCRIPTION
Estradiol valerate (¦Â-Estradiol 17-valerate) is a synthetic estrogen widely used in combination with other steroid hormones in hormone replacement therapy agents.
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
2
Compound Sets
17
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
Selleckchem Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
93
Molecular Weight
356.24
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
4
Aromatic Ring Count
1
cLogP
5.35
TPSA
46.53
Fraction CSP3
0.7
Chiral centers
5.0
Largest ring
6.0
QED
0.74
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Indication
prostate cancer, hypoestrogenism, menopause, vaginal atrophy
Disease Area
oncology, endocrinology, obstetrics/gynecology
Target
ESR1
Estrogen/progestogen Receptor
Estrogen Receptor/ERR
MOA
Estrogen receptor agonist
Pathway
Vitamin D Related/Nuclear Receptor
Source data

